Mesenchymal stem cell–gut microbiota interaction in the repair of inflammatory bowel disease: an enhanced therapeutic effect

Dickson Kofi Wiredu Ocansey1,3†, Li Wang2†, Jingyan Wang1, Yongmin Yan1, Hui Qian1, Xu Zhang1, Wenrong Xu1 and Fei Mao1*

Abstract
Background: Several investigations affirm that, patients with inflammatory bowel disease (IBD) exhibit dysbiosis characterized by restricted biodiversity and imbalanced bacterial composition intertwined with immune dysregulation. The interaction between stem cells and gut microbiota is a novel and highly promising field that could add up to a better understanding of the gut physiology, as well as therapeutic improvement towards diseases like IBD. Through direct contact or release of products and/or metabolites, gut bacteria regulate gut homeostasis, damage repair, regeneration and differentiation of stem cells. In the same way, mesenchymal stem cells (MSCs) produce similar effects including restoration of gut–microbiome composition.

Body: We reviewed the anti-inflammatory, antimicrobial, pathogenic bacterial clearance, proliferation and tissue remodeling effects of mesenchymal stem cells (MSCs) and fecal microbiota transplantation (FMT) as separate transplants in IBD, and the outcome of the interaction between MSCs and gut microbiota.

Conclusion: The two therapies share several points of connection in therapeutics with enhanced functionalities in their interaction with each other. Focused investigations of MSC–gut bacteria interactions could lead to a novel discovery in therapeutics. We also anticipate an improved clinical remission rate in a combined FMT–MSC transplantation approach in IBD than the current single FMT or MSC approach.

Keywords: Mesenchymal stem cell therapy, Fecal microbiota transplant, Inflammatory bowel disease, MSC–gut bacteria interaction, Combined therapy

Background
Microbiome is known to partake in a wide range of important roles such as hematopoiesis [1], immune system modulation and development [2], neurologic signaling [3], host metabolism [4], and remodeling of bone mass [5] in the mammalian tissue. Characterized by chronic and relapsing intestinal mucosa inflammation, inflammatory bowel disease (IBD) is generally defined as either Crohn’s disease (CD) or ulcerative colitis (UC) with related causes being genetic, gut (microbial and immune changes), environmental and lifestyle factors. The participation of gut–microbiota in the pathophysiology of IBD has lately been highlighted with the outcome suggesting a crucial function of the gut–microbiota in the intestinal inflammation and even in colorectal cancer [6]. Even though it has not clearly been determined how the dysbiosis observed participates in intestinal inflammation, it is however recognized that several of the documented IBD susceptibility genes are linked with recognizing and
processing bacterial cells, which agrees with certain function of the gut–microbiota in IBD pathogenesis. On the basis of this, some therapeutic experimental models and clinical trials that seek to correct the alterations within the gut–microbiota which include fecal microbiota transplantation and probiotics administration have shown promising outcomes in IBD [7].

Transplanted MSCs have also shown significant contributions towards the recovery of many diseases including IBD via engraftment and differentiation into functional reparative cells, replacement of injured tissues as well as the use of immune modulators or trophic resources. These mostly result in expressed paracrine factors that ultimately promote tissue repair [8]. MSC therapy has also been demonstrated to dampen inflammation, restore gut microbiome alteration and enhance pathogenic bacterial eradication culminating in reestablished gut health in IBD. Even though little is known about MSC–gut microbiota interaction, the few available studies indicate a positive communication which results in enhanced functions of both components. In this document, we review the therapeutic application of gut microbiota (FMT) and MSC in IBD, emphasizing on the common characteristic effects of these two therapies and how their interactions potentiate the functions of each other. We also discuss the way forward to a possible future FMT–MSC combined therapeutic approach.

Features that differentiate UC and CD
Regardless of the fact that both UC and CD are labelled as IBD, there are significant differences between the two. These differences invariably affect their pathology and response to therapy. In CD, the location of the inflammation may occur anywhere along the digestive tract with deeper ulceration, thickened colon wall, patched inflammatory pattern, granulomas and possible fistulas, strictures and fissures in the complicated state [9]. On the other hand, UC is typically restricted to the large intestine (colon) with surface mucus lining ulceration, thinner and continuous inflammation of the colon wall with no patches, no granulomas, fistulas, strictures and fissures [9, 10].

A recent report indicates that at the pathway level, virus infection and autoimmune pathways are upregulated in CD but not in UC whilst pattern recognition-mediated innate immune pathways (TLR2 and TLR4) are appreciably raised in UC but not in CD [11]. This report identifies different intervention targets for effective treatment of the two diseases. The microRNA signatures of body fluids and tissues like saliva, blood and colon have also indicated significant variations between UC and CD. Schaefer et al. documented that, about 26 miRNAs are changed in UC and CD colon biopsies relative to non-IBD controls. Out of this number, UC was associated with the differential expression of 6 miRNAs whilst CD was associated with 10 miRNAs in matched colon tissues. In whole blood, altered expression of 9 miRNAs were linked to UC whilst 6 miRNAs were linked to CD. Similar alterations in expression were also noticed in the saliva of UC and CD patients [12]. This aberrant miRNA expression profiles are believed to contribute the IBD pathogenesis. Other approaches that have been employed to reveal the differences between these two diseases include signaling pathways and gene expressions [13], specific inflammasome [14] and extracellular matrix turnover profile [15].

Role of gut microbiota in IBD
Researches sprouting out within the cross point between IBD and the microbiota are very promising and believed to soon significantly impact daily medical practice. Microbial profiles sometimes called “signatures” vary appreciably and enough between the diseased and the healthy individual [16]. The gut–microbiota has physiological functions that provide several health imparts to the host in relation to nutrition, pathogen protection, metabolism and immunity [17]. However, recent advances in clinical and experimental research have discovered alterations in the function and composition of the gut–microbiota (dysbiosis) in several diseases including IBD [18]. Though the exact cause of IBD is still not known, it is documented that its pathogenesis is closely linked with dysbiosis with the most consistent observation being reduced bacterial diversity; a decrease of Firmicutes, and an increase of Proteobacteria [7].

Research has confirmed several specific role of certain gut bacteria in relation to IBD pathogenesis and recovery. In some of these investigations, a reduction in Firmicutes such as F. prausnitzii, Roseburia inulinivorans, Blautia faecis, Clostridium lavalense and Ruminococcus torques were noticed in persons having CD compared to the healthy individuals [19, 20]. The quantity of F. prausnitzii in the gut correlated significantly with risk of ileac CD relapse after surgery and its population reconstitution after relapse is linked with the maintenance of clinical remission. Again, a decrease of Roseburia spp. predisposes a healthy individual to a high genetic risk for IBD [21]. However, an increase in Proteobacteria, mainly E. coli (38%), was observed in active CD patients compared to only 6% in healthy people [22]. Other increased bacteria population associated with IBD include mucolytic bacteria Ruminococcus torques and Ruminococcus gnavas [23]. These gut bacteria adhere to the intestinal epithelium consequently affecting intestinal permeability, altering diversity and composition of gut–microbiota and triggering inflammatory responses through the
regulation of inflammatory genes expression leading to intestinal inflammation [24].

Aside bacteria, the gut microbiota comprise of other microorganisms including fungi and viruses which are possible key factors in bacterial population control and even direct participation in the pathogenesis of IBD [16]. With regards to specific distortions of enteric virome in IBD, it is known that bacteriophages of the Caudovirales and Microviridae families are the most abundant enteric virome within the healthy populace. In IBD patients however, these bacteriophages richness especially the Caudovirales family are increased compared to the healthy individual [25]. Several other factors link a healthy gut to dysbiosis and consequently, inflammatory gut (Fig. 1).

**Fecal microbiota transplantation in IBD**

IBD is believed to exhibit a complex interplay of dysbiosis and dysregulation of the immune system [26]. Evolving therapies that seek to correct these abnormalities include the growing interest to rectify the underlying dysbiosis via the application of FMT. While this therapy has indicated great efficacy in refractory *Clostridium difficile* infections, its general application is yet to be definitely proven in IBD [27]. In one study, FMT administered once weekly via enema for 6 weeks was superior to placebo with some differences in efficacy in relation to donors [28]. In a similar study, no noteworthy variation in endoscopic and clinical remission was witnessed between participants who received their own gut microbiome and those who received from donors when the FMT was administered through nasoduodenal tube [29]. This raises concerns on donor selection, route and frequency of administration, FMT preparation and receiver factors amongst others in the quest to obtaining optimum therapeutic influence. There is therefore the need for specifically designed experiments in and around these optimal factors in FMT application. An earlier research that investigated FMT treatment efficacy in IBD documented an overall clinical remission rate of 45% (54/119) in patients during follow-up and concluded that, FMT is safe but has variable efficacious outcome in IBD treatment [26]. Furthermore, a recent systemic review and metaanalysis also asserted that, in spite of the small number of identified studies and the low quality of evidence, FMT is promising and capable of increasing the percentage of clients that achieve clinical remission in UC [30]. Some of these clinical trials are presented in Table 1.

**Application in UC**

In a study of 7 children with ulcerative colitis, 4/7 responded to treatment 4 weeks post FMT administration based on their pediatric UC activity index. Detailed analysis indicated a shift of the class *Clostridia*, viromic and metabolomics profiles of respondents toward the donor’s microbiota composition. These changes alongside alterations in fecal concentrations of several other metabolites correlated with improved clinical remission [40]. A randomized clinical trial involving 73 adults divided participants into two groups of 38/73 (who received anaerobically prepared pooled donor FMT) and 35/73 (who received autologous FMT). At the eighth week post administration, 12/38 (32%) as against 3/35 (9%) of participants who received pooled donor FMT and autologous FMT respectively achieved primary end

---

**Fig. 1** The road of a healthy gut to an inflamed gut. Many factors are associated with the alteration of gut microbiome which ultimately lead to dysbiosis. The altered microbiota diversity and composition coupled with other intestinal epithelial changes lead to inflammation in the gut, characterized by increased inflammatory genes expression.
| Type of IBD          | Study design/aim                | Volume/frequency                                      | Route                     | Observed outcome                                                                                           | References |
|---------------------|--------------------------------|-------------------------------------------------------|---------------------------|-----------------------------------------------------------------------------------------------------------|------------|
| UC                  | Efficacy evaluation            | 24 g/250 ml 20 g/100 ml 3 days                       | Nasojejunal tube Enema    | 1/5 (20%) had clinical response with effective augmentation by FMT Side effects included temporal rise in     | [31]       |
|                     |                                |                                                       |                           | C-reactive protein and fever                                                                             |            |
| UC                  | Prospective and uncontrolled   | 250 ml 5 rounds                                       | Duodenal gastroscopy      | Significantly reduced clinical index scores for diarrhea, abdominal pain, blood stool and intestinal          | [32]       |
|                     | study                           |                                                       |                           | mucosal lesions No serious adverse reactions                                                             |            |
| CD with inflammatory mass | Efficacy and safety evaluation | Repeated every 3 months after initial dose            | Mid-gut Transendoscopic  | 68% (17/25) and 52% (13/25) clinical response and clinical remission at 3 months respectively At 6, 12 and 18 | [33]       |
|                     |                                |                                                       | enteral tubing            | months, clinical remission were 48% (12/25), 32% (8/25) and 22.7% (5/22), respectively No severe adverse   |            |
|                     |                                |                                                       |                           | events                                                                                                    |            |
| UC                  | Pilot study on feasibility and | 165 ml/day 5 days                                     | Enema                     | 7/9 (78%) had clinical response within 1 week 6/9 (67%) maintained clinical response at 1 month No serious   | [34]       |
|                     | safety                           |                                                       |                           | adverse event                                                                                              |            |
| UC                  | Randomized controlled trial    | Days 1 and 21                                        | Nasoduodenal tube         | 7/23 (30.4%) had clinical remission in intention-to-treat analysis 7/17 (41.2%) had clinical remission in the pe- | [29]       |
|                     |                                |                                                       |                           | r-protocol analysis 2 patients had FMT-linked adverse events Responders had similar microbiota as that of    |            |
|                     |                                |                                                       |                           | donors by 12 weeks                                                                                                                                                 |            |
| Fistulizing CD      | A case study                   | 150 ml once                                          | Mid-gut gastroscopy       | Significantly alleviated fever, improved bloody purulent stool and decreased abdominal pain, with reduced  | [35]       |
|                     |                                |                                                       |                           | intraperitoneal inflammatory mass at 1 week Clinical remission at 1 month Sustained clinical remission with   |            |
|                     |                                |                                                       |                           | resolved mass without exudation at 3 months                                                             |            |
| Refractory CD       | Pilot study on feasibility,    | Once                                                  | Mid-gut                   | 86.7% (26/30) and 76.7% (23/30) had clinical improvement and remission respectively at 1 month            | [36]       |
|                     | efficacy and safety            |                                                       |                           |                                                                                                           |            |
Table 1 (continued)

| Type of IBD | Study design/aim                                                                 | Volume/frequency | Route     | Observed outcome                                                                                                                                                                                                                                                                                                                                                          | References |
|-------------|----------------------------------------------------------------------------------|------------------|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Mild to severe CD | Evaluation of efficacy in the short term and risk factors in the long term | 184 frequencies | Mid-gut   | Clinical response and clinical remission were 45% (9/20) and 20% (4/20) in patients with adverse events, and 75.6% (60/119) and 63.0% (75/119) in patients without adverse events respectively. Adverse events of 21.7% in manually prepared FMT and 8.7% in automated preparations. Manual or automatic purification of fecal microbiota had no correlation with the efficacy of FMT.                                                                 | [37]       |
| UC          | Randomised placebo-controlled trial                                              | 5 days per week for 8 weeks | Colonoscopy Enemas | 11/41 (27%) who received FMT as against 3/40 (8%) who received placebo had steroid-free clinical remission with endoscopic remission or response. Adverse events recorded in 32/41 (78%) FMT and 33/40 (83%) placebo patients with serious events in 2 FMT and 1 placebo patients.                                                                                                                                 | [38]       |
| CD          | Prospective open-label study (uncontrolled)                                      | Once             | Colonoscopy | 58% (11/19) had clinical response. Significant shift in fecal microbial diversity and composition toward donor's profile. Increased Treg cells (CD4$^+$CD25$^+$CD127$^-$) noticed in recipients' lamina propria following FMT. No serious adverse events recorded.                                                                                                                                                  | [39]       |

Summary of some of the IBD clinical trials on the feasibility, safety and efficacy of FMT. Different study designs across varying degrees and types of IBD employing distinct techniques, volumes and frequencies of FMT administration, yielded different patients' responses.

CD Crohn's disease, UC ulcerative colitis
point remission. However only five of the 12 retained the clinical remission up to the 12th month [41]. Similarly, 9/36 (24%) patients who received FMT and 2/37 (5%) who received placebo attained clinical remission at 7 weeks post administration in another randomized controlled trial [28]. According to Paramsothy et al., specific bacteria and metabolites linked with the achievement of clinical therapeutic response in FMT include Roseburia inulivorans and Eubacterium hallii, and secondary bile acids and short-chain fatty acids respectively [42]. With respect to donor’s stool, the same clinical trial again reported that, enriched Bacteroides is associated with improved remission of patients while Streptococcus species is linked with no response to FMT [42].

Application in CD
Increasing evidence indicates the promising outcome of FMT as an encouraging treatment option for Crohn’s disease (CD). However, the frequency of FMT for CD treatment remains unclear. In the first study that demonstrate that FMT could be a possible therapeutic option for CD, metagenomic analysis of stool microbiota indicated an evidence of FMT engraftment in 7/9 (78%) of participants. Analysis based on pediatric Crohn’s disease activity index showed 7/9 participants in clinical remission at 2 weeks and 5/9 patients who did not receive further medication in clinical remission at 6 and 12 weeks [43]. In another study, Vaughn et al. documented an encouraging clinical response rate of 11/19 (58%) in CD patients who received FMT treatment [39]. This was a consequence of a significant shift in patients’ fecal microbial diversity and composition towards their donor’s profile. Patients’ lamina propria also witnessed increased regulatory T-cells (CD4+ CD25+ CD127lo) following FMT treatment. A single FMT administration in children with active IBD including CD, resulted in a clinical response rate of 57% and 28% at 1 and 6 months post FMT respectively. Adverse events ranged from mild to moderate and self-limiting reactions [44]. This indicates that, although single FMT administration is safe in children, it is confronted with short-lived clinical response. In the quest to retain a long term remission in the first treatment in CD, Li et al. estimated the optimal timing for a second FMT administration. They concluded that, patients with CD could be given the second course of FMT in less than 4 months after the first FMT [45].

It is undoubtedly clear that the exploitation of the gut microbiome could produce a great therapeutic novelty. However, there is poor and limited knowledge on microbiota modulation in IBD, hence the necessity for further in-depth investigations. In order to achieve a reliable safety and efficacy assessment with solid conclusion on FMT application in IBD, it is essential to mount more randomized controlled trials. Again, the frequency of FMT administration, standardization of microbiome analysis and donor selection should also be intently investigated. Other optimal parameters of FMT effects with regard to route of administration, volume, preparation, and the type and disease severity should also be defined. Additionally, studies to assess the long-term FMT-mediated maintenance of clinical remission in CD and UC should be carried out.

MSC therapy in IBD
The functions of MSCs spanning from cell replacement to immunosuppression and trophic factors production, have gain a lot of interest with increasing application in regenerative medicine and immune intervention in both experimental models and clinical trials. MSCs are known to interact with inflammatory cytokines and greatly influence both adaptive and innate immune systems via producing immunomodulatory particles that control the progression of inflammation by affecting cells like macrophages, T cells, NK cells, dendritic cells and B cells [46, 47]. By employing these properties, MSC application in IBD has been applied to achieve cellular replacement, immunosuppression and other trophic actions, together resulting in highly promising outcomes in clinical trials [48, 49] and experimental studies [50, 51]. MSC-therapy in IBD is mainly administered through systemic infusion or local inoculation. MSC extracts have also been applied in certain conditions. In one study that sought to overcome the low homing capacity of MSCs and augment their therapeutic influence, MSC extracts were used instead of whole cells in treating severe refractory IBD. Results indicated that the MSC extracts were highly potent than whole MSCs in reducing DAI, nitrite levels and the histological score. The extract totally inhibited the induction of inflammatory cytokines, recovered the destroyed epithelial barriers and shifted macrophage from M1 to M2 via reducing the levels of Chemokine (C–X–C motif) ligand 9 (CXCL9), monocyte chemoattractant protein-1 (MCP1) and inducible nitric oxide synthase (iNOS), but increasing the expression of Chemokine (C–C motif) ligand 1 (CCL1), IL-10, and Arg-1 [52]. Some clinical trials involving MSC-based therapy in IBD are summarized in Table 2.

Application in UC
Several clinical trial studies have investigated the safety and therapeutic influence of MSCs in UC. In one of such studies, the diffused and deep ulcers formed as well as severely inflamed mucosa of 30/36 (83%) participants were greatly improved at 1 month post MSC treatment [53]. Systematic review and meta-analysis of clinical and experimental studies was recently conducted on
Out of the 15 studies included in the analysis, 7 were human (n = 216) trials and 8 were animal (n = 132) studies. The data showed that animals given MSCs had significantly lower DAI, longer colon length and lower histopathological score compared with control group. The clinical trials analysis also indicated an obvious recovery with single-arm studies analysis of four trials demonstrating an increased healing rate of 0.787 post-MSC treatment \[59\]. One of the challenges of MSC-based therapy is the issue of dosage and frequency.

**Table 2** Application of MSC-based therapy in IBD clinical trials

| IBD type                                      | Study design                        | MSC source          | Outcome                                                                 | References |
|----------------------------------------------|-------------------------------------|---------------------|--------------------------------------------------------------------------|------------|
| Moderate to severe UC                        | Phase I/II randomized controlled   | Human umbilical cord| 30/36 patients showed good response with markedly improved mucosa at 1 month Decreased median Mayo score and histology score during follow up No evident adverse reactions after MSC infusion | \[53\]     |
| CD                                           | Randomized controlled study         | Human umbilical cord| Decreased CDAI, HBI, and corticosteroid dosage with remarkable mucosal recovery at 12 months Concomitant anal fistula was improved in six patients treated with MSC | \[54\]     |
| Luminal CD refractory to biologic therapy    | Phase 2, open-label, multicenter    | Bone marrow         | Improved recovery associated with reduced CDAI and CDEIS scores 7/15 patients had a clinical response, 8/15 had clinical remission, and 7/15 had endoscopic improvement | \[55\]     |
| Complex perianal fistulas in CD              | Phase 3 randomized double-blind    | Adipose             | 53/107 (50%) of MSC treated patients achieved combined remission in intention-to-treat protocol 53/103 (51%) of modified intention-to-treat populations achieved combined remission | \[48\]     |
| UC                                           | Two years observation after MSC     | Bone marrow         | 72.7% of UC patients who received MSC treatment achieved significant response Reduced activity of autoimmune inflammation and stimulated reparative process in the intestinal mucosa Increased duration of remission, reduced risk of recurrence of disease, and reduced frequency of hospitalizations | \[56\]     |
| UC                                           | –                                   | Bone marrow         | Increased in the duration of remission in patients with chronic recurrent and continuous recurrent course of UC Reduced risk of relapse, and reduced frequency of hospital admissions compared with medication therapy | \[57\]     |
| Crohn's perianal fistula                     | MSC safety study in pregnancy       | Adipose             | Fertility and pregnancy outcomes were not affected by MSC treatment No signs of treatment-related malformations were observed in the neonates by their respective pediatricians | \[58\]     |

Summary of some of the IBD clinical trials on the feasibility, safety and efficacy of MSC therapy. Different study designs across varying degrees and types of IBD employing distinct techniques and sources of MSC yielded different patients' responses. CDAI Crohn's disease activity index, HBI Harvey-Bradshaw index, CDEIS Crohn's disease endoscopic index of severity.
of administration. In investigating the dose dependency of MSC therapy in colitis, Robinson et al. reported that, increasing doses above $1 \times 10^6$ MSCs does not add additional therapeutic benefits than $1 \times 10^6$ MSCs in preventing enteric neuropathy associated with intestinal inflammation [60]. Several other recent studies have also focused on enhancing the inherent therapeutic properties of MSCs to ensure consistency and efficacy in their application. For an example, the co-administration of the experimental drug MIS416 and human umbilical cord MSCs, exerted significant therapeutic efficiency consequently alleviating the symptoms of colitis as compared to the single MSC treatment [61]. The MIS416 was found to modulate the colon immune milieu via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and toll-like receptor 9 (TLR9) signaling activation, causing the MSCs to be readily recruited to the injury site to inhibit inflammation. Again, treatment of colitis with preconditioned MSCs resulted in an improved therapeutic effects characterized by increased body weight recovery, reduced DAI, reduced histological colitis score and decreased destruction of the epithelial barrier [62]. Further analysis revealed the activation of the extracellular signal-regulated kinases (ERK) pathway (inducing anti-apoptotic effects), suppression of T cell proliferation and inhibition of inflammatory cytokines TNFα and IL-2 whilst triggering the production of the anti-inflammatory cytokine IL-10 in T-cells.

Application in CD
A randomized controlled clinical trial analysis reported that, umbilical cord derived MSCs were generally effective in the treatment of CD although it produced mild adverse events. At 12 months post-treatment, the Crohn's Disease activity index (CDAI), Harvey–Bradshaw index (HBI) and corticosteroid dosage of the MSC-group, had reduced by $62.5 \pm 23.2$, $3.4 \pm 1.2$, and $4.2 \pm 0.84$ mg/day respectively as compared to the control group which had $23.6 \pm 12.4$, $1.2 \pm 0.58$, and $1.2 \pm 0.35$ mg/day reduction [54]. With regards to luminal CD, an open-label multicenter study involving 16 participants having CD refractory to biologic therapy was carried out. Among the 15 participants who completed the study, 12 (80%) had clinical response, 8 (53%) had clinical remission and 7 (47%) had endoscopic improvement [55]. The potent immunomodulatory effects exerted by MSCs during CD treatment is via complex paracrine and cell–cell contact mediated actions involving antigen-specific T cells [63].

Perianal CD occurs in approximately 25% of individuals with CD and is notoriously very difficult to treat with available biologics and surgical procedures. However, MSC therapy has shown encouraging outcomes. In their phase 3 randomized double-blind controlled trial, Panés et al. treated complex perianal fistulas in Crohn's disease with allogeneic expanded adipose-derived MSCs. Results of intention-to-treat protocol indicated that, 53/107 (50%) of MSC treated patients achieved combined remisison as against 36/105 (34%) of placebo treated patients. In modified intention-to-treat populations, MSC verses placebo resulted in 53/103 (51%) and 36/101 (36%) remission rates respectively [48]. Other documented evidence of MSC efficacy and safety in Crohn's fistula include complete healing in 21/26 patients (80.8%) in modified per protocol analysis and 27/36 patients (75.0%) in modified intention-to-treat analysis [64] and 71% in a phase II clinical trial [65]. These among other studies have shown the efficacy and safety of MSC-based therapy in CD even in those that do not respond to conventional and/or biological treatments.

Despite the increasing trend in interest and significant clinical efficacy of MSC therapy in IBD, it is still confronted with unresolved challenges. Just as discussed in FMT, MSC therapy also has issues of administration protocol (route, dosage, schedule), origin and type of MSCs (autologous or allogeneic), quality of preparation and selection of experimental or clinical design to ensure optimum therapeutic impart. Conditions that potentiate the functions and desired effects of MSCs should further be investigated.

Combined therapeutic effects
Fundamentally, the gut microbiota and host's immune system inter-depend on each other by shaping the development, composition and functions of one another [66]. Invariably, MSC-therapy does not only aim at restoring the desired host immune response but also correct the altered gut microbiota whilst FMT restores gut dysbiosis resulting in dampened inflammation. These functions interlace and may even yield higher therapeutic influence when co-administered since the few existing investigations report the close communication and enhanced functionality of each other in their interactions [47, 67–70, 71].

The therapeutic imparts of MSCs do not necessarily rely on their full cellular engraftment, but rather on their capability to express trophic factors and hinder pathogenic immune reactions, favoring tissue repair [72, 73]. To this effect, conditioned-MSCs effectively alleviated colitis at both the inductive and recovery phases by producing these factors of anti-inflammation, proliferation and tissue remodeling [73]. It has also been demonstrated that, the microbiota intensely participate in the modulation of several host metabolic pathways, which cause the activation of immune-inflammatory axes and signaling pathways [74]. These functions among other desired
therapeutic effects have been documented in the use of both FMT and MSC therapies in IBD.

MSC–microbe interactions have a pronounced influence on the functions of MSC including its immunomodulation and migration, which are pivotal in the therapeutic utility of MSC across various diseases including IBD [70]. Known examples of the interaction between these two therapies are summarized in Table 3. Gastrointestinal bacteria are capable of inducing immune-regulatory mediator secretions, cytokine gene transcription and surface protein expressions in MSCs [70]. While Xiao et al. revealed that, microbiota alters the differentiation potentials and improves the immunomodulation ability of bone marrow MSCs [67], another research also indicated that a restored diversity of gut microbiome, reinstates bone marrow-derived MSCs from premature age-associated deterioration and loss of cell power of growth and division (senescence) [47]. Again, Nagashima et al. recently discovered a sub-epithelial mesenchymal cells which did not only induce gut microbiota diversity but also regulated the production of IgA which preserves gut symbiotic equilibrium [69]. Likewise, MSCs given by infusion caused an initial alteration in Bacteroidetes/Firmicutes ratio, which sustained intestinal mucosal function and homeostasis; believed to be valuable in hepatocyte repair [75]. Based on these findings, it could be hypothesized that FMT which seeks to restore gut microbial diversity and composition, may as well improve the functionality of MSCs and vice versa when co-administered in IBD treatment. This provides a promising area for future studies in IBD therapy. Figure 2 illustrates the main characteristic functional points of connection between the two therapies.

Pathogenic bacteria eradication
The gut–microbiota is known to effectively contribute to host defense against pathogens by preventing their colonization [78], secreting direct target bacteriocin [79], antimicrobials peptides and RegIIIγ [80] and triggering immune cells [81]. For lack of or altered gut microbiome, germ-free and antibiotic treated mice are known to be extremely susceptible to enteric bacterial pathogens like Listeria monocytogenes, Shigella flexneri, Salmonella Typhimurium and Citrobacter rodentium [82, 83]. Gut microbiota mount host defense against pathogenic colonization by competitive nutrient utilization and by secreting antimicrobial factors like lactic acid, bacteriocin and RegIIIγ [18] in addition to improving mucosal barrier functions and innate immunity [84]. On the other hand, it was demonstrated that MSCs significantly decreased bacteremia and mortality in sepsis partly by improving bacterial clearance and the phagocytic properties of blood monocytes [85], enhancing pathogen clearance [86] and by prostaglandin E2-dependent reprogramming of host macrophages which upregulates interleukin-10 production [87]. MSCs again, augmented the antibacterial function of neutrophil granules [88], Harman et al. recently reported growth inhibition and cell membrane depolarization effects of equine derived/conditioned medium MSCs on S. aureus and E. coli with specific antimicrobial peptides [89] whilst Johnson et al. reported similar findings even in chronic drug-resistant bacterial infection [90]. Other antimicrobial secretomes of MSCs known to inhibit bacterial growth and/or kill them directly include cathelicidin [91], lipocalin 2 [92], elafin [89] and beta defensin 2 [93]. In the event of pathogen encounter, intestinal epithelial MSCs switch towards secretory epithelial cells differentiation [92], hence rapid proliferation and differentiation of goblet and Paneth cells. These cells produce resistin, mucin, trefoil factor 3 (TFF3), lysozyme and defensin to speed up bacterial clearance [94]. Toll-like receptors (TLRs) expressed on intestinal epithelial cells and mucosal dendritic cells (DCs) surfaces are known to be immune regulatory receptors and present bacterial antigens to the immune system [95], thereby differentiating commensals from pathogenic microbes. While TLR2, TLR5 and TLR4 identify extracellular microbes, TLR3 specifically recognizes viral particles with TLR4 playing a crucial function as a first protective line against probable pathogenic bacteria [96]. Both MSCs (by expression) [97, 98] and microbiome [99] are known to immunologically regulate the TLRs to enhance pathogenic eradication and stimulate anti-inflammation, even against antimicrobial resistant pathogens [80].

Anti-inflammation
It has been shown that gut–microbiota induces the differentiation and expansion of colonic Regulatory T-cells (Tregs) [100] and the development of Th17 cells [101], both of which play roles in the regulation or suppression of other immune system cells. F. prausnitzii, was found to exert anti-inflammatory effect via producing IL-10 and inhibiting the secretion of inflammatory cytokines like IL-12 and IFN-γ [102]. The same gut bacterial is again associated with the release of anti-inflammatory molecules like salicylic acid within the gut lumen [103]. This anti-inflammatory effect is exerted on both immune cells and intestinal epithelial cells via specifically stimulating a new type of human IL-10 producing Treg cells [104] and bacterial-derived peptide inhibition of NFKB activation [105] respectively.

MSCs also trigger the upregulation of several anti-regulatory modulators such as Foxp3+ regulatory T cells, Th17 and Th1 cells in CD and Th2 cells in UC [106, 107]. They again upregulate Treg-cells, IL-10 and TGF-β whilst decreasing IL-17 [108]. Other studies
Table 3 The influence of gut–bacteria on the functions of MSCs

| Gut bacteria                                      | Source of MSC    | Experimental condition | Pathways/secretomes involved                                                                 | Outcome of interaction                                                                 | References |
|--------------------------------------------------|------------------|------------------------|---------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|------------|
| Specific-pathogen-free (SPF) gut microbiota      | Bone marrow      | DSS-induced colitis    | Cell metabolic, HIF-1/Inflammatory signaling, and neurodegenerative pathways                  | Altered MSC differentiation potential<br>Enhanced immunomodulation capacity<br>Decreased disease activity index | [67]       |
| Lactobacillus acidophilus                        | Canine adipose   | In vitro               | Increased transcription of key immunomodulatory genes like COX2, IL6 and IL8<br>Significantly increased PGE2 | No induction of MSC death, degeneration or diminished proliferation<br>No effect on MSC migration | [70]       |
| Salmonella typhi                                 | Canine adipose   | In vitro               | Increased transcription of key immunomodulatory genes like COX2, IL6 and IL8<br>No induction of antigen-presenting phenotype<br>Increased capacity of MSCs to inhibit mitogen-induced T-cell proliferation<br>Induction and expression of PPARγ, IL-6, IL-8, HGF, COX2, CD54 and PGE2<br>Impeded MSC migration | | [70]       |
| Restored composition and diversity of gut microbiota with Lactobacillus | Bone marrow      | Chronic hypoxic rats   | –                                                                                           | Restored defect of senescence, poor cell proliferation, cell cycle arrest and multi-lineage differentiation deficiency in MSCs<br>Reduced β-galactose accumulation | [47]       |
| Lactobacillus rhamnosus GG                       | Lamina propria of the villus | Intestinal radioprotection in vitro | TLR2 and COX-2 dependent induction<br>Lactobacillus rhamnosus GG produced LTA, which then primed the epithelial stem cell niche to protect epithelial stem cells by activating macrophages and PGE2 secreting MSCs | | [76]       |
| Helicobacter pylori                              | Bone marrow      | GIT infection by H. pylori | Over-expression of TNFα and CCL2<br>TNFα leads to activation of NF-κB-dependent pathway | Stimulated migration of MSC                                                                 | [77]       |

This presents a sum-up of documented impacts of gut microbiome including some pathogenic bacteria on the functions of MSCs. In each demonstration, certain functions of MSCs were mostly improved with no distortion to the inherent properties.

PPARγ: peroxisome proliferator activator receptor gamma, IL: interleukin, HGF: hepatocyte growth factor, COX2: cyclooxygenase 2, PGE2: prostaglandin 2, NF-κB: Nuclear Factor-kappa B, TLR2: toll-like receptor 2, LTA: lipoteichoic acid, CCL2: C-C motif Chemokine ligand 2, TNFα: tumor necrosis factor α.
have also reported MSCs to increase the secretion of pro-inflammatory cytokines Th1 and Th17 while downregulating inflammatory cytokines IFN-γ, TNF-α, IL-6, IL-2 and IL-17 [109, 110]. According to Ahmed et al., genetic expression of inflammatory markers (IL-23, IFN-γ, TNF-α, ICAM-1) within the intestinal mucosa of MSC treated mice appreciably lowered, resulting in a significant improvement in weight gain, stool condition, as well as normal histopathology of tissues analyzed [111].

Kol et al. reported that, while particular in vitro manipulations could produce an antigen presenting cell (APC) phenotypic shift in MSCs, the communication with physiologically important bacteria including even pathogenic bacteria *Salmonella Typhi*, did not trigger this potential harmful phenotypic shift [70]. Further investigations indicated that, intestinal bacteria-MSCs interactions triggered the enzymatic precursor for PGE2 (i.e., COX2) and pleiotropic cytokine IL6, which are both anti-inflammatory and pro-inflammatory mediators that inhibit Th17 differentiation, lymphocyte proliferation and M1 differentiation of monocytes [70, 112]. The various secretomes elicited within the MSC and FMT administered environment and their resultant effects are shown in Fig. 3.

**Proliferation and tissue remodeling**

Regardless of the source of MSCs and the route of administration, they have been shown to be capable of engrafting into inflamed intestinal and mesenteric lymph nodes in IBD and self-proliferating as well as inducing the proliferation of intestinal cells to repair and replace damaged tissues. By self-proliferation, MSCs trigger colonic repair by differentiating into several cells and dampening inflammation [113] and by differentiating into fibroblast [51]. Many other researches have indicated the ability of MSC to regenerate, remold and induce proliferation of tissues [114, 115]. For instance, a systemic infusion of MSCs improved the proliferation and differentiation of intestinal epithelial cells [114, 116] while MSCs-conditioned medium (MSC-CM) also strongly induced cell proliferation, tissue remodeling and repair of intestinal submucosa injury in colitis [73]. MSCs within the intestine direct epithelial cells lineage differentiation [117, 118] and secrete RANKL (TNFSF11), which is known to induce the development, differentiation and maintenance of M cells [69, 119, 120].

Gut microbiota constitute a complex ecosystem within which a progressive cross communication modulates several host cellular activities as well as metabolic pathways, including actively shaping and remodeling the mucosa of intestinal tissues [70]. Through NOD2 sensors, the gut–microbiota is associated with gut epithelial cell regeneration [121]. Although little is known about
microbiome–MSCs interactions, certain researches have already documented the close communication between microbiota (and their products) and stem cells in the intestinal niche; potentially in the crypt, assisting stem cells in their roles of epithelial regeneration and homeostasis post-damage repair [121, 122]. In one of such investigations, a common peptidoglycan motif to all bacteria, triggered stem cell survival, leading to a strong cyto-protection against oxidative stress-mediated cell death [121]. Soontararak et al. reported that, the administration of induced pluripotent stem cells (earlier proven to be functionally equal to adipose derived MSCs), did not only trigger increase in Lgr5+ intestinal stem cells, but also upsurge the intestinal epithelial cells proliferation, angiogenesis and even significantly restored alterations in the gut microbiome of IBD mice [68].

**Discussions and future perspective**

Currently, many preliminary investigations have demonstrated the therapeutic potentials of FMT in IBD [29] and gastrointestinal disorders [123, 124], among few other conditions. The outcome alongside reviews and meta-analysis have asserted that, FMT application in IBD is promising, effective and safe. However, it is confronted with challenges including minor to serious adverse events, unknown long-term stability of remission, low overall quality of available studies, undefined study designs and treatment protocols, donor and recipient factors as well as poorly defined efficacy endpoint. Again, the low remission rates witnessed in FMT application in IBD studies could be attributed to the complex interplay between microbial, environmental [125], genetic and immunologic [28, 126] factors that take part in the pathogenesis of IBD, therefore the introduction of just a new set of gut microbiota may not necessarily produce the expected outcome. Similarly, MSC therapy is confronted with similar challenges in its application in IBD in spite of the successes witnessed. While these challenges are being battled out in the mission to improve their therapeutic efficacy, there is the need to mount more investigations bent on throwing more light on microbiome–MSC interactions. Although it is asserted that, MSC–microbiome communications occur via TLRs [98] and NLRs [127], the direct and specific proof of such contacts and their resulting impact on the immunomodulatory capability of MSCs remain undefined. Gut microbiome along with other modulators may even contribute to establishing engrafted MSC’s niche in IBD during MSC therapy, and determine whether the given MSCs will take on a pro-inflammatory or an anti-inflammatory phenotype [128, 129]. More researches focused in this area may result in the discovery of a novel product/mechanism of their communication in therapy, since the few available data appear highly encouraging.

Although it is not certain whether it is the MSC-activated effects that enhance the microbiome diversity or rather the opposite, by and large, both effects within the colon epithelium improve each other’s functions, consequently encouraging intestinal epithelial cells regeneration, dampened inflammation, pathogen eradication and angiogenesis. While FMT and MSC therapies are confronted with several challenges in their utility in IBD, a combined therapeutic approach may successfully yield an increased clinical response and remission since both therapies do not only share common characteristics in impart but also influence each other to enhance and potentiate their functionality and therapeutic efficacy. Also, the identification and subsequent administration
of only the specific gut–bacteria responsible for eliciting desired effects in IBD treatment, would yield better outcome than the administration of the bulk fecal material. Moreover, more studies geared toward elucidating not only host–microbiome interactions but also cross-microbiome interactions are expected to improve FMT. Finally, for a prospective utility of an FMT–MSC combined therapy in IBD and other conditions, there is the need to further investigate the interaction between the components of these two therapies and clearly understand the mechanisms underlying the enhanced effects on each other.

Considering the increasing interest on these two therapies and the highly promising outcome of MSC–gut microbiota communication in the few available documents, this field would soon attract more investigations and applications across many conditions with significant daily medical practice impact.

Conclusion

The participation of gut–microbiota in the pathophysiology of IBD is well established. The gut–microbiota provide several health benefits to the host including pathogen protection, cellular regeneration and immune modulation. With the background that, alterations in the function and composition of the gut–microbiota, coupled with immune-dysregulation lead to chronic and relapsing intestinal mucosa inflammation (i.e. IBD), the application of MSCs and FMT as therapies in IBD have gain much interest. These two therapies seek to resolve the underlying dysbiosis and repair damages. Irrespective of the successes, increasing trend in interest and the significant clinical efficacy of both therapies in IBD, they are still confronted with several unresolved challenges. In the phase of these challenges, stem cells–gut microbiota interaction is fast emerging as a novel and highly promising field. In the communication between MSCs and gut microbiota, the functions of each component are improved; in that while MSC reinstates gut microbiota communication and diversity, FMT also potentiates MSC activities. This could lead to higher clinical remission rates when applied together in the IBD environment, hence the need to explore further.

Abbreviations

IBD: inflammatory bowel disease; MSCs: mesenchymal stem cells; FMT: fecal microbiota transplantation; CD: Crohn’s disease; UC: ulcerative colitis; NK cells: natural killer cells; DA: disease activity index; CXCL: Chemokine (C–X–C motif) ligand; MCP: monocyte chemoattractant protein; iNOS: inducible nitric oxide synthase; CCL: Chemokine (C–C motif) ligand; IL: interleukin; NOD2: nucleotide-binding oligomerization domain-containing protein 2; TLR: toll-like receptor; ERK: extracellular signal-regulated kinases; TNF: tumor necrosis factor; HBI: Harvey–Bradshaw index; CDAI: Crohn’s disease activity index; CDEIS: Crohn’s disease endoscopic index of severity; PPARγ: peroxisome proliferator activator receptor gamma; HGF: hepatocyte growth factor; COX2: cyclooxygenase 2; PGE: prostaglandin; NF-κB: nuclear factor-kappa B; LTA: lipoteichoic acid; TFF3: trefoil factor 3; DC: dendritic cell; Th cells: T-helper cells; Tregs: regulatory T-cells; IFN: interferon; ICAM: intercellular adhesion molecule; APC: antigen presenting cell.

Authors’ contributions

DWKO: conception and design, collection and/or assembly of data, data analysis and interpretation, and manuscript writing. LW: conception and collection, design and assembly of data, data analysis and interpretation, and manuscript writing. JW: collection and/or assembly of data and data analysis. YY: provision of study material and interpretation. HQ: data analysis and interpretation. XZ: collection and/or assembly of data. WX: study design, data analysis and interpretation. FMT: study design, data analysis and interpretation, manuscript writing, and final approval of manuscript. All authors read and approved the final manuscript.

Funding and acknowledgments

This study was funded by the National Natural Science Foundation of China (Grant No. 81670022), the Scientific Research Foundation of Jiangsu University (Grant No. FCJJ2015023), Nanjing health science and technology development special fund project (Grant No. YKK18207), the opening project of the Key Laboratory of Embryo Molecular Biology, Ministry of Health of China, and Shanghai Key Laboratory of Embryo and Reproductive Engineering (Grant No. HF201601), Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions and Zhenjiang Key Laboratory of High Technology Research on Exosomes Foundation and Transformation Application (Grant No. SS2018003). All authors approved the final version of the article.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Key Laboratory of Medical Science and Laboratory Medicine of Jiangsu Province, School of Medicine, Jiangsu University, 301 Xuefu Road, Zhenjiang 212013, Jiangsu, People’s Republic of China. 2 Huaian Maternity and Children’s Hospital, Huaian 223002, Jiangsu, People’s Republic of China. 3 Directorate of University Health Services, University of Cape Coast, Cape Coast, Ghana.

Received: 17 October 2019 Accepted: 17 December 2019

Published online: 23 December 2019

References

1. Khosravi A, Yáñez A, Price JG et al (2014) Gut microbiota promote hematopoiesis to control bacterial infection. Cell Host Microbe 15:374–381. https://doi.org/10.1016/j.chom.2014.02.006

2. Macpherson AJ, Harris NL (2004) Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol 4:478–485. https://doi.org/10.1038/nri1373

3. Yano JM, Yu K, Donaldson GP et al (2015) Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161:264–276. https://doi.org/10.1016/j.cell.2015.02.047

4. Canfora EE, Jocken JW, Blaak EE (2015) Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol 11:577–591. https://doi.org/10.1038/nrendo.2015.128

5. Cho I, Yamanishi S, Cox L et al (2012) Antibiotics in early life alter the murine colon microbiome and adiposity. Nature 488:621–626. https://doi.org/10.1038/nature11400

6. Allen J, Sears CL (2019) Impact of the gut microbiome on the genome and epigenome of colon epithelial cells: contributions to colorectal
7. Matsuoka K, Kanai T (2015) The gut microbiota and inflammatory bowel disease. Semin Immunopathol 37:47–55. https://doi.org/10.1007/s00281-014-0454-4

8. Kang J, Zhang L, Luo X et al (2018) Systematic exposition of mesenchymal stem cell for inflammatory bowel disease and its associated colorectal cancer. Biomed Res Int 2018:1–16. https://doi.org/10.1155/2018/9652817

9. Kilcoyne A (2016) Inflammatory bowel disease imaging: current practice and future directions. World J Gastroenterol 22:917. https://doi.org/10.3748/wg.v22.i3.917

10. Schaefer JS, Attumi T, Opekun AR et al (2015) MicroRNA signatures to analyze gene expressions and signaling pathways reveals unique purine gene dysregulation profiles that distinguish between CD and UC. Inflamm Bowel Dis 15:971–984. https://doi.org/10.1002/ibd.20893

11. Lang L, Tang S, Baker SS et al (2019) Difference in pathomechanism between Crohn's disease and ulcerative colitis revealed by colon transcriptome. Inflamm Bowel Dis 25:722–731. https://doi.org/10.1093/ibd/iyz359

12. Schaefer JS, Attumi T, Opekun AR et al (2015) MicroRNA signatures differentiate Crohn's disease from ulcerative colitis. BMC Immunol 16:5. https://doi.org/10.1186/s12865-015-0069-0

13. Rybaczzyk L, Rzomiarek A, Circle K et al (2009) New bioinformatics approach to analyze gene expressions and signaling pathways reveals unique purine gene dysregulation profiles that distinguish between CD and UC. Inflamm Bowel Dis 15:971–984. https://doi.org/10.1002/ibd.20893

14. Lazaridis L-D, Pistiki A, Giamarellos-Bourboulis EJ et al (2017) Activation of NLRP3 inflammasome in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis. Dig Dis Sci 62:2348–2356. https://doi.org/10.1007/s10620-017-4609-8

15. Mertens JH, Manon-Jensen T, Jensen MD et al (2017) Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles in the enteric virome in inflammatory bowel disease. Clin J Gastroenterol 11:1–10. https://doi.org/10.1007/s13073-017-0067-4

16. Philippe M, Harry S (2015) Gut microbiota and inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. https://doi.org/10.4172/1755-8166.S2-006

17. van Nood E, Vrieze A, Nieuwdorp M et al (2013) Duodenal infusion of Faecalibacterium prausnitzii for recurrent Clostridium difficile. N Engl J Med 368:407–415. https://doi.org/10.1056/NEJMoa1205037

18. Moayedi P, Surette MG, Kim PT et al (2015) Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149:102. https://doi.org/10.1053/j.gastro.2015.04.001

19. Rossen NG, Fuentes S, van der Spek MJ et al (2015) Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149:110. https://doi.org/10.1053/j.gastro.2015.03.045

20. Imdad A, Nicholson MR, Tanner-Smith EE et al (2017) Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD012774

21. Angelberger S, Reinisch W, Makristathis A et al (2015) Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 108:1620–1630. https://doi.org/10.1038/ajg.2013.257

22. Tian Y, Zhou Y, Huang S et al (2019) Fecal microbiota transplantation for ulcerative colitis: a prospective clinical study. BMC Gastroenterol 19:116. https://doi.org/10.1186/s12866-019-1010-4

23. He Z, Li F, Zhu J et al (2017) Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn's disease complicated with obstructive stricture. Sci Rep 7:4753. https://doi.org/10.1038/s41598-017-04984-z

24. Kunde S, Pham A, Boczynski S et al (2013) Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 56:597–601. https://doi.org/10.1097/MPG.0b013e318292faoo

25. Zhang F-M, Wang H-G, Wang M et al (2013) Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn's disease. World J Gastroenterol 19:7213–7216. https://doi.org/10.3748/wjg.v19.i41.7213

26. Cui B, Feng Q, Wang H et al (2015) Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol 30:51–58. https://doi.org/10.1111/jgh.12727

27. Wang H, Cui B, Li Q et al (2018) The safety of fecal microbiota transplantation for Crohn's disease: findings from a long-term study. Adv Ther 35:1935–1944. https://doi.org/10.1007/s12325-018-0800-3

28. Paramsothy S, Kamm MA, Kaakoush NO et al (2017) Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389:1218–1228. https://doi.org/10.1016/S0140-6736(17)30182-4

29. Vaughn BP, Vatanen T, Allegretti JR et al (2016) Increased intestinal microbial diversity following fecal microbiota transplant for active Crohn’s disease. Inflamm Bowel Dis 22:1182–2190. https://doi.org/10.1097/MIB.0000000000000893

30. Nusbaum DJ, Sun F, Rem J et al (2018) Gut microbiota and metabolite profiles after fecal microbiota transplantation in pediatric ulcerative colitis patients. FEMS Microbiol Ecol. https://doi.org/10.1093/femsec/ffy133

31. Costello SP, Hughes PA, Waters O et al (2018) Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis. JAMA 321:156. https://doi.org/10.1001/jama.2017.16046

32. Paramsothy S, Nielsen S, Kamm MA et al (2019) Specific bacteria and metabolites associated with response to fecal microbiota transplantation in patients with ulcerative colitis. Gastroenterology 156:1440. https://doi.org/10.1053/j.gastro.2018.12.001

33. Suskind DL, Brittnacher MJ, Wahbeh G et al (2015) Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease. Inflamm Bowel Dis 21:556–563. https://doi.org/10.1097/MIB.0000000000000307

34. Goyal A, Yeh A, Bush BR et al (2018) Safety, clinical response, and microbiome findings following fecal microbiota transplant in children with inflammatory bowel disease. Inflamm Bowel Dis 24:410–421. https://doi.org/10.1093/ibd/ixo335

35. Li P, Zhang T, Xiao Y et al (2019) Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn's disease. Appl Microbiol Biotechnol 103:349–360. https://doi.org/10.1007/s00253-018-9447-x
46. Trounson A, McDonald C (2015) Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 17:11–22. https://doi.org/10.1016/j. stem.2015.06.007

47. Xing J, Ying Y, Mao C et al (2018) Hypoxia induces senescence of bone marrow mesenchymal stem cells via altered gut microbiota. Nat Commun 9:2090. https://doi.org/10.1038/s41467-018-04453-9

48. Panés J, García-Olmo D, Van Assche G, Colombel J (2016) Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet 388:1281–1290

49. Dhere T, Copland I, Garcia M, Chiang K (2016) The safety of autologous and metabolically fit bone marrow mesenchymal stromal cells in medically refractory Crohn’s disease—a phase 1 trial with three doses. Aliment Pharmacol Ther 44:471–481

50. Jiang W, Tan Y, Cai M et al (2018) Hypoxia induces senescence of bone marrow mesenchymal stem cells via altered gut microbiota. Nat Commun 9:2090. https://doi.org/10.1038/s41467-018-04453-9

51. Martin Arranz E, Martin Arranz MD, Robredo T, Mancheño-Corvo P (2018) Endoscopic submucosal injection of adipose-derived mesenchymal stem cells ameliorates TNBS-induced colitis in rats and prevents stenosis. Stem Cell Res Ther 9:95. https://doi.org/10.1186/s13287-018-0690-2

52. Song J, Kang HJ, Hong JS et al (2017) Umbilical cord-derived mesenchymal stem cell exerts anti-inflammatory effects in mice by re-polarizing intestinal macrophages. Sci Rep 7:9412. https://doi.org/10.1038/s41598-017-09827-5

53. Hu J, Zhao G, Zhang L et al (2016) Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis. Exp Ther Med 12:2983–2989. https://doi.org/10.3892/etm.2016.3724

54. Zhang J, Lv S, Liu X et al (2018) Umbilical cord mesenchymal stem cell treatment for Crohn’s disease: a randomized controlled clinical trial. Gut Liver 12:73–78. https://doi.org/10.5009/gnl17035

55. Forbes GM, Sturm MJ, Leong RW et al (2014) A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn’s disease refractory to biologic therapy. Clin Gastroenterol Hepatol 12:64–71. https://doi.org/10.1016/j.cgh.2013.06.021

56. Laiznbek LB, Kniazev OV, Konopliannikov AG et al (2010) Allogeneic mesenchymal stromal cells in patients with ulcerative colitis: two years of observation. Eksp Klin Gastroenterol 11:3–15

57. Laiznbek LB, Kniazev OV, Parfenov AI et al (2010) Transplantation of allogeneic mesenchymal stem cells from the bone marrow increases duration of remission and reduces the risk of ulcerative colitis relapse. Eksp Klin Gastroenterol 3:5–10

58. Sanz-Baro R, García-Arranz M, Guadalajara H et al (2015) First-in-human case study: pregnancy in women with Crohn’s perianal fistula treated with adipose-derived stem cells: a safety study. Stem Cells Transl Med 4:598–602. https://doi.org/10.5966/sctm.2014-0255

59. Shi X, Chen Q, Wang F (2019) Mesenchymal stem cells for the treatment of ulcerative colitis: a systematic review and meta-analysis of experimental and clinical studies. Stem Cell Res Ther 10:266. https://doi.org/10.1186/s13287-019-1336-4

60. Robinson AM, Rahman AA, Miller S et al (2017) The neuroprotective effects of human bone marrow mesenchymal stem cells are dose-dependent in TNBS colitis. Stem Cell Res Ther 8:87. https://doi.org/10.1186/s13287-017-0540-3

61. Lee B-C, Shin N, Lee JY et al (2018) MiS146 enhances therapeutic functions of human umbilical cord blood-derived mesenchymal stem cells against experimental colitis by modulating systemic immune milieu. Front Immunol. https://doi.org/10.3389/fimmu.2018.01078

62. Yang FY, Chen R, Zhang X et al (2018) Preconditioning enhances the therapeutic effects of mesenchymal stem cells on colitis through PGE2-mediated T-cell modulation. Cell Transplant 27:1352–1367. https://doi.org/10.1080/0963689718803034

63. Ciccocioppo R, Cangemi GC, Kuzlik P et al (2015) Ex vivo immunosuppressive effects of mesenchymal stem cells on Crohn’s disease mucosal T cells are largely dependent on indoleamine 2,3-dioxygenase activity and cell-cell contact. Stem Cell Res Ther 6:137. https://doi.org/10.1186/s13287-015-0122-1

64. Cho Y, Park K, Yoon S, Song K (2015) Long-term results of adipose-derived stem cell therapy for the treatment of Crohn’s fistula. Stem Cells Transl Med 4:532–537

65. Guadalajara H, Herreraos D, De-La-Quintana P, Trebol J (2012) Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Colorectal Dis 27:595–600. https://doi.org/10.1007/s00384-011-1350-1

66. Kamada N, Nunez G (2014) Regulation of the immune system by the resident intestinal bacteria. Gastroenterology 146:1477–1488

67. Xiao E, He L, Wu Q et al (2017) Microbiota regulates bone marrow mesenchymal stem cell lineage differentiation and immunomodulation. Stem Cell Res Ther 8:213. https://doi.org/10.1186/s13287-017-0670-7

68. Soontararak S, Chow L, Johnson V et al (2018) Mesenchymal Stem Cells (MSC) Derived from Induced Pluripotent Stem Cells (iPSC) equivalent to adipose-derived MSC in promoting intestinal healing and microbiome normalization in mouse inflammatory bowel disease model. Stem Cells Transl Med 7:456–467. https://doi.org/10.1002/sctm.17-0305

69. Nagashima K, Sawa S, Nitta T et al (2017) Identification of subepithelial mesenchymal cells that induce IgA and diversify gut microbiota. Nat Immunol 18:675–682. https://doi.org/10.1038/ni.3732

70. Kol A, Foutouhi S, Walker NJ et al (2014) Gastrointestinal microbes interact with canine adipose-derived mesenchymal stem cells in vitro and enhance immunomodulatory functions. Stem Cells Dev 23:1831–1843. https://doi.org/10.1089/scd.2014.0128

71. Iwamura C, Bouladoux N, Belkai Y et al (2017) Sensing of the microbiota by NOD1 in mesenchymal stromal cells regulates murine hemapoiesis. Blood 129:171–176. https://doi.org/10.1182/blood -2016-07-723742

72. Uccelli A, Laroni A, Freedman MS (2011) Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 10:649–656. https://doi.org/10.1016/S1474-4422(11)70121-1

73. Watanabe S, Arimura Y, Nagaishi K et al (2014) Conditioned mesenchymal stem cells produce pleiotropic gut homeostatic factors. J Gastroenterol 49:270–282. https://doi.org/10.1007/s00535-013-0901-3

74. Nicholson JK, Holmes E, Kinross J et al (2012) Host–gut microbiota metabolic interactions. Science 336:1262–1267. https://doi.org/10.1126/ science.1233813

75. Dong X, Feng X, Liu J et al (2019) Characteristics of intestinal microecology during mesenchymal stem cell-based therapy for mouse acute liver injury. Stem Cells Int 2019:1–14. https://doi.org/10.1155/2019/2405393

76. Reihl TE, Alvarado D, Ee X et al (2019) Lactobacillus rhamnosus GG protects the intestinal epithelium from radiation injury through release of lipoteichoic acid, macrophage activation and the migration of mesenchymal stem cells. Gut 68:1003–1013. https://doi.org/10.1136/gutjnl -2018-316226

77. Ferrand J, Lehours P, Schmid-Alliana A et al (2011) Helicobacter pylori infection of gastrointestinal epithelial cells in vitro induces mesenchymal stem cell migration through an NF-kB-dependent pathway. PLoS ONE 6:e29007. https://doi.org/10.1371/journal.pone.0029007

78. Buffie C, Palmer E (2013) Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 13:790–801

79. Huang T, Zhang X, Pan J et al (2016) Purification and characterization of a novel cold shock protein-like bacteriocin synthesized by Bacillus thuringiensis. Sci Rep 6:336:1325–1329

80. Krasnodembskaya A, Samarai A, Song Y et al (2012) Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative
et al. Clin Trans Med (2019) 8:31

87. Nemeth K, Leelahavanichkul A, Yuen P et al (2009) Bone marrow stromal cell attenuates sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Cell Mol Physiol 302:L1003–L1013. https://doi.org/10.1152/ajpcell.00180.2011

88. Brandau S, Jakob M, Bruderek K et al (2014) Mesenchymal stem cells augment the antibacterial activity of neutrophil granulocytes. PLoS ONE 9:e114201

89. Harman RM, Yang S, He MK, Van de Walle GR (2017) Antimicrobial peptides secreted by equine mesenchymal stromal cells inhibit the growth of bacteria commonly found in skin wounds. Stem Cell Res Ther 8:157. https://doi.org/10.1186/s13287-017-0610-0

90. Johnson V, Webb T, Norman A et al (2017) Activated mesenchymal stem cells interact with antibodies and host innate immune responses to control chronic bacterial infections. Sci Rep 7:9575. https://doi.org/10.1038/s41598-017-08311-4

91. Kościuczk E, Lisowski P, Jarczak J et al (2012) Cathelicidins: family of antimicrobial peptides, a review. Mol Biol Rep 39:10597–10970

92. Gupta N, Kasemsukbaya A, Kapetanaki M et al (2012) Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 67:533–539

93. Sung D, Chang Y, Sung S et al (2016) Antibacterial effect of mesenchymal stem cells against Escherichia coli is mediated by secretion of beta-defensin-2 via toll-like receptor 4 signaling: antibacterial effects of MSCs via beta-defensin-2. Cell Microbiol 18:424–436

94. Kurashima Y, Yamamoto D, Nelson S et al (2017) Mucosal mesenchymal stem cells: secondary barrier and peripheral educator for the gut immune system. Front Immunol. https://doi.org/10.3389/fimmu.2017.01787

95. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783–801

96. Vijay-Kumar M, Aitken JD, Carvalho FA et al (2010) Metabolic syndrome augments the antibacterial activity of neutrophil granulocytes. PLoS ONE 5:e13088

97. Roulis M, Flavell RA (2016) Fibroblasts and myofibroblasts of the intestinal epithelium. J Immunol 183:5738–5747. https://doi.org/10.4049/jimmunol.1502038

98. Blount ML, Costabile A, Alarcon GM et al (2015) Understanding mammalian gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 112:7620–7625. https://doi.org/10.1073/pnas.1423186112

99. Yiu JHC, Dorweiler B, Woo CW (2017) Interaction between gut microbiota and altered gut microbiota in mice lacking toll-like receptor 5. Science 357:819–823. https://doi.org/10.1126/science.aal4189

100. Karahani M, Pinto MD, Pacheco S et al (2015) Identification of metabolic changes in Faecalibacterium prausnitzii deficient in Crohn's disease. Proc Natl Acad Sci USA 112:7620–7625. https://doi.org/10.1073/pnas.1423186112

101. Denning DW, Newton T, Dunlop DD et al (2016) Human umbilical cord mesenchymal stem cells ameliorate mice trinitrotoluene sulfonic Acid (TNBS)-induced colitis. Cell Transplant 20:1395–1408. https://doi.org/10.3727/096369105x848925

102. Akikiyama K, Chen C, Wang D, Xu X (2012) Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand–FAS-mediated T cell apoptosis. Cell Stem Cell 10:544–555

103. Abdel Salam AG, Ata HM, Salman TM, Rashed LA (2014) Potential thera- peutic utility of mesenchymal stem cells in inflammatory bowel disease in mice. Int Immunopharmacol 22:515–521. https://doi.org/10.1016/j.intimp.2014.07.030

104. Pouya S, Heidari M, Baghaei M, Asadzadeh Aghdaei H (2018) Study the effects of mesenchymal stem cell conditioned medium injection in mice model of acute colitis. Int Immunopharmacol 54:86–94. https://doi.org/10.1016/j.intimp.2017.11.001

105. Liang L, Dong C, Chen X, Fang Z (2011) Human umbilical cord mesenchymal stem cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15:42–49

106. Parekkadan B, Upadhyay R, Dunham J, Iwamoto Y (2011) Bone marrow stromal cell transplants prevent experimental enterocolitis and require host CD11b+ splenocytes. Gastroenterology 140:966–975

107. Chao K, Zhang S, Yao J, He Y (2014) Imbalances of CD4(+) T-cell sub- groups in Crohn's disease and their relationship with disease activity and prognosis. J Gastroenterol Hepatol 29:1810–1814

108. Johnson V, Webb T, Norman A et al (2017) Activated mesenchymal stem cells interact with antibodies and host innate immune responses to control chronic bacterial infections. Sci Rep 7:9575. https://doi.org/10.1038/s41598-017-08311-4

109. Johnson V, Webb T, Norman A et al (2017) Activated mesenchymal stem cells interact with antibodies and host innate immune responses to control chronic bacterial infections. Sci Rep 7:9575. https://doi.org/10.1038/s41598-017-08311-4

110. Johnson V, Webb T, Norman A et al (2017) Activated mesenchymal stem cells interact with antibodies and host innate immune responses to control chronic bacterial infections. Sci Rep 7:9575. https://doi.org/10.1038/s41598-017-08311-4

111. Johnson V, Webb T, Norman A et al (2017) Activated mesenchymal stem cells interact with antibodies and host innate immune responses to control chronic bacterial infections. Sci Rep 7:9575. https://doi.org/10.1038/s41598-017-08311-4

112. Johnson V, Webb T, Norman A et al (2017) Activated mesenchymal stem cells interact with antibodies and host innate immune responses to control chronic bacterial infections. Sci Rep 7:9575. https://doi.org/10.1038/s41598-017-08311-4

113. Johnson V, Webb T, Norman A et al (2017) Activated mesenchymal stem cells interact with antibodies and host innate immune responses to control chronic bacterial infections. Sci Rep 7:9575. https://doi.org/10.1038/s41598-017-08311-4

114. Gong W, Guo M, Han Z et al (2016) Mesenchymal stem cells stimulate intestinal stem cells to repair radiation-induced intestinal injury. Cell Death Dis 7:e2387. https://doi.org/10.1038/cddis.2016.276

115. La Francesca S, Aho JM, Barron MR et al (2018) Long-term regeneration and remodeling of the pig esophagus after circumferential resection using a retrievable synthetic scaffold carrying autologous cells. Sci Rep 8:4123. https://doi.org/10.1038/s41598-018-22401-x

116. Chen Q, Yan L, Wang C, Wang W (2013) Mesenchymal stem cells allevi- ate TNBS-induced colitis by modulating inflammatory and autommune responses. World J Gastroenterol 19:4702–4717

117. Hinz B (2016) Myofibroblasts. Exp Eye Res 142:56–70. https://doi.org/10.1016/j.expeye.2015.07.009

118. Roulis M, Flavell RA (2016) Fibroblasts and myofibroblasts of the intestinal lamina propria in physiology and disease. Differentiation 92:116–131. https://doi.org/10.1016/j.diff.2016.05.002

119. Knoop KA, Kumar N, Butler BR et al (2009) RANKL is necessary and suffi- cient to initiate development of antigen-sampling M cells in the intestinal epithelium. J Immunol 183:5738–5747. https://doi.org/10.4049/jimmunol.0900153

120. Neyal M, Sodhi C, Jia H et al (2012) Toll-like receptor 4 is expressed on intestinal stem cells and regulates their proliferation and apop- tosis via the p35 up-regulated modulator of apoptosis. J Biol Chem 287:37296–37308

121. Opreta R, Bratu M, Opreta B, Diaconescu B (2016) Fecal transplanta- tion—the new, inexpensive, safe, and rapidly effective approach in the treatment of gastrointestinal tract diseases. J Med Life 9:160–162

122. Oprita R, Bratu M, Opreta B, Diaconescu B (2016) Fecal transplantation— the new, inexpensive, safe, and rapidly effective approach in the treatment of gastrointestinal tract diseases. J Med Life 9:160–162

123. Oprita R, Bratu M, Opreta B, Diaconescu B (2016) Fecal transplantation— the new, inexpensive, safe, and rapidly effective approach in the treatment of gastrointestinal tract diseases. J Med Life 9:160–162
126. Dave M, Papadakis KA, Faubion WA Jr (2014) Immunology of inflammatory bowel disease and molecular targets for biologics. Gastroenterol Clin North Am 43:405
127. Kim H-S, Shin T-H, Yang S-R et al (2010) Implication of NOD1 and NOD2 for the differentiation of multipotent mesenchymal stem cells derived from human umbilical cord blood. PLoS ONE 5:e15369. https://doi.org/10.1371/journal.pone.0015369
128. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM (2010) A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS ONE 5:e10088. https://doi.org/10.1371/journal.pone.0010088
129. Anton K, Banerjee D, Glod J (2012) Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion. PLoS ONE 7:e35036. https://doi.org/10.1371/journal.pone.0035036

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.